BiotechTube

Methylprednisolone + Prednisone + Rituximab

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Wegener's Granulomatosis or Microscopic Polyangiitis

Conditions

Wegener's Granulomatosis or Microscopic Polyangiitis

Trial Timeline

Jul 6, 2015 → Jun 7, 2022

NCT ID
NCT02115997

About Methylprednisolone + Prednisone + Rituximab

Methylprednisolone + Prednisone + Rituximab is a approved stage product being developed by Roche for Wegener's Granulomatosis or Microscopic Polyangiitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02115997. Target conditions include Wegener's Granulomatosis or Microscopic Polyangiitis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02115997ApprovedCompleted

Competing Products

2 competing products in Wegener's Granulomatosis or Microscopic Polyangiitis

See all competitors
ProductCompanyStageHype Score
RituximabRocheApproved
85
Abatacept + placeboBristol Myers SquibbPhase 3
76

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
saquinavir/ritonavir + atazanavir/ritonavirApproved
85